Intraoperative imaging in ovarian cancer: Fact or fiction?

Lucia M A Crane, Marleen Van Oosten, Rick G. Pleijhuis, Arash Motekallemi, Sean Christopher Dowdy, William Arthur Cliby, Ate G J Van Der Zee, Gooitzen M. Van Dam

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of research that is on the verge of clinical implementation. As each tumor has its unique biologic profile, selection of the most promising targets is essential. In this review, we focus on target finding in ovarian cancer, a disease in which fluorescence imaging may be of value in both adequate staging and in improving cytoreductive efforts, and as such may have a beneficial effect on prognosis. Thus far, tumor-targeted imaging for ovarian cancer has been applied only in animal models. For clinical implementation, the five most prominent targets were identified: folate receptor α, vascular endothelial growth factor, epidermal growth factor receptor, chemokine receptor 4, and matrix metalloproteinase. These targets were selected based on expression rates in ovarian cancer, availability of an antibody or substrate aimed at the target approved by the Food and Drug Administration, and the likelihood of translation to human use. The purpose of this review is to present requirements for intraoperative imaging and to discuss possible tumor-specific targets for ovarian cancer, prioritizing for targets with substrates ready for introduction into the clinic.

Original languageEnglish (US)
Pages (from-to)248-257
Number of pages10
JournalMolecular Imaging
Volume10
Issue number4
DOIs
StatePublished - Jul 2011

Fingerprint

Ovarian Neoplasms
Tumors
cancer
Imaging techniques
Optical Imaging
tumors
Neoplasms
Fluorescence
Substrates
Vascular Endothelial Growth Factor Receptor
Antibodies
Chemokine Receptors
United States Food and Drug Administration
Animals
Matrix Metalloproteinases
Folic Acid
Epidermal Growth Factor Receptor
Availability
fluorescence
animal models

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Biotechnology
  • Molecular Medicine
  • Biomedical Engineering
  • Condensed Matter Physics

Cite this

Crane, L. M. A., Van Oosten, M., Pleijhuis, R. G., Motekallemi, A., Dowdy, S. C., Cliby, W. A., ... Van Dam, G. M. (2011). Intraoperative imaging in ovarian cancer: Fact or fiction? Molecular Imaging, 10(4), 248-257. https://doi.org/10.2310/7290.2011.00004

Intraoperative imaging in ovarian cancer : Fact or fiction? / Crane, Lucia M A; Van Oosten, Marleen; Pleijhuis, Rick G.; Motekallemi, Arash; Dowdy, Sean Christopher; Cliby, William Arthur; Van Der Zee, Ate G J; Van Dam, Gooitzen M.

In: Molecular Imaging, Vol. 10, No. 4, 07.2011, p. 248-257.

Research output: Contribution to journalArticle

Crane, LMA, Van Oosten, M, Pleijhuis, RG, Motekallemi, A, Dowdy, SC, Cliby, WA, Van Der Zee, AGJ & Van Dam, GM 2011, 'Intraoperative imaging in ovarian cancer: Fact or fiction?', Molecular Imaging, vol. 10, no. 4, pp. 248-257. https://doi.org/10.2310/7290.2011.00004
Crane, Lucia M A ; Van Oosten, Marleen ; Pleijhuis, Rick G. ; Motekallemi, Arash ; Dowdy, Sean Christopher ; Cliby, William Arthur ; Van Der Zee, Ate G J ; Van Dam, Gooitzen M. / Intraoperative imaging in ovarian cancer : Fact or fiction?. In: Molecular Imaging. 2011 ; Vol. 10, No. 4. pp. 248-257.
@article{4a9be69a6861430a88993f7580a18fb4,
title = "Intraoperative imaging in ovarian cancer: Fact or fiction?",
abstract = "Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of research that is on the verge of clinical implementation. As each tumor has its unique biologic profile, selection of the most promising targets is essential. In this review, we focus on target finding in ovarian cancer, a disease in which fluorescence imaging may be of value in both adequate staging and in improving cytoreductive efforts, and as such may have a beneficial effect on prognosis. Thus far, tumor-targeted imaging for ovarian cancer has been applied only in animal models. For clinical implementation, the five most prominent targets were identified: folate receptor α, vascular endothelial growth factor, epidermal growth factor receptor, chemokine receptor 4, and matrix metalloproteinase. These targets were selected based on expression rates in ovarian cancer, availability of an antibody or substrate aimed at the target approved by the Food and Drug Administration, and the likelihood of translation to human use. The purpose of this review is to present requirements for intraoperative imaging and to discuss possible tumor-specific targets for ovarian cancer, prioritizing for targets with substrates ready for introduction into the clinic.",
author = "Crane, {Lucia M A} and {Van Oosten}, Marleen and Pleijhuis, {Rick G.} and Arash Motekallemi and Dowdy, {Sean Christopher} and Cliby, {William Arthur} and {Van Der Zee}, {Ate G J} and {Van Dam}, {Gooitzen M.}",
year = "2011",
month = "7",
doi = "10.2310/7290.2011.00004",
language = "English (US)",
volume = "10",
pages = "248--257",
journal = "Molecular Imaging",
issn = "1535-3508",
publisher = "Decker Publishing",
number = "4",

}

TY - JOUR

T1 - Intraoperative imaging in ovarian cancer

T2 - Fact or fiction?

AU - Crane, Lucia M A

AU - Van Oosten, Marleen

AU - Pleijhuis, Rick G.

AU - Motekallemi, Arash

AU - Dowdy, Sean Christopher

AU - Cliby, William Arthur

AU - Van Der Zee, Ate G J

AU - Van Dam, Gooitzen M.

PY - 2011/7

Y1 - 2011/7

N2 - Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of research that is on the verge of clinical implementation. As each tumor has its unique biologic profile, selection of the most promising targets is essential. In this review, we focus on target finding in ovarian cancer, a disease in which fluorescence imaging may be of value in both adequate staging and in improving cytoreductive efforts, and as such may have a beneficial effect on prognosis. Thus far, tumor-targeted imaging for ovarian cancer has been applied only in animal models. For clinical implementation, the five most prominent targets were identified: folate receptor α, vascular endothelial growth factor, epidermal growth factor receptor, chemokine receptor 4, and matrix metalloproteinase. These targets were selected based on expression rates in ovarian cancer, availability of an antibody or substrate aimed at the target approved by the Food and Drug Administration, and the likelihood of translation to human use. The purpose of this review is to present requirements for intraoperative imaging and to discuss possible tumor-specific targets for ovarian cancer, prioritizing for targets with substrates ready for introduction into the clinic.

AB - Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of research that is on the verge of clinical implementation. As each tumor has its unique biologic profile, selection of the most promising targets is essential. In this review, we focus on target finding in ovarian cancer, a disease in which fluorescence imaging may be of value in both adequate staging and in improving cytoreductive efforts, and as such may have a beneficial effect on prognosis. Thus far, tumor-targeted imaging for ovarian cancer has been applied only in animal models. For clinical implementation, the five most prominent targets were identified: folate receptor α, vascular endothelial growth factor, epidermal growth factor receptor, chemokine receptor 4, and matrix metalloproteinase. These targets were selected based on expression rates in ovarian cancer, availability of an antibody or substrate aimed at the target approved by the Food and Drug Administration, and the likelihood of translation to human use. The purpose of this review is to present requirements for intraoperative imaging and to discuss possible tumor-specific targets for ovarian cancer, prioritizing for targets with substrates ready for introduction into the clinic.

UR - http://www.scopus.com/inward/record.url?scp=79959752763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959752763&partnerID=8YFLogxK

U2 - 10.2310/7290.2011.00004

DO - 10.2310/7290.2011.00004

M3 - Article

C2 - 21521557

AN - SCOPUS:79959752763

VL - 10

SP - 248

EP - 257

JO - Molecular Imaging

JF - Molecular Imaging

SN - 1535-3508

IS - 4

ER -